BISPECIFIC ANTIBODIES TARGETING CD137 AND USES THEREOF FOR ANTI-CANCER IMMUNOTHERAPY
Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for p95HER2 or for CD73, bispecific antibodies comprising a first antigen binding region that binds to p95HER2 or CD73 and a second antigen binding region that binds to an immune checkpoint molecule or a...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
23.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for p95HER2 or for CD73, bispecific antibodies comprising a first antigen binding region that binds to p95HER2 or CD73 and a second antigen binding region that binds to an immune checkpoint molecule or an immune stimulatory molecule, and antibody-drug conjugates thereof. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, bispecific antibodies or antibody drug conjugates thereof, and methods of use thereof. The methods of use include method of treating cancer. |
---|---|
Bibliography: | Application Number: AU20220389917 |